Vaccinations and People With Disabilities

Questionnaires and Focus Groups Based Quantitative & Qualitative Study of Vaccine Hesitancy and Confidence Among At-risk and Marginalized Populations: Persons With Special Needs, Intellectual Disabilities and Congenital Anomalies

The goal of this observational study is to learn about vaccinations hesitancy, delay or avoidance in children with chronic diseases, congenital anomalies or disabilities. The main questions it aims to answer are:

• Attitudes of caregivers towards vaccinating their children, obstacles that postpone vaccinations, and the status of vaccinations of these children.

Participants will fill out questionnaires and some will be included in focused groups for the qualitative part of the study.

Researchers will compare the vaccinations status of the research group to their siblings' status as well as the published national records of vaccination compliance.

Study Overview

• Status: Recruiting
• Conditions: Compliance, Patient; Pediatric Disorder; Congenital Disorders; Vaccine Refusal; Disability, Intellectual

Detailed Description

Global vaccines programs prevent infectious diseases, congenital anomalies and cancer [1,2]. Full and partial avoidance of vaccines, or postponing vaccines, may lead to morbidity, disability and mortality. This is particularly significant among children and adults with special needs, intellectual and developmental disabilities, and congenital anomalies, which are at-risk groups, together representing over 15% of the general population [3,4]. Studies have shown that this population is particularly vulnerable when it comes to infectious diseases, hospitalizations, sexually transmitted diseases, abuse and neglect [5,6,7]. Furthermore, this is a marginalized population, with (in average) a lower socioeconomic status and at a lower level of education of themselves and their caregivers [8]. The reasons for hesitance, avoidance or selectivity of vaccines by the caregivers are not comprehensively characterized. Therefore, the investigators outline our thoughts and Insights from our ongoing work, for over two decades, with this population. In the investigators experience, when doctors and nurses ask the patients and their caregivers what are the reasons for less-then-optimal vaccination state, there are several explanations: concurrent illnesses that made them postpone vaccinations, access challenges, being preoccupied with many other health tasks, and paradoxically the fear that the child is too fragile for receiving the vaccine or that the vaccine itself will do harm. Also, some may be wrongly advised about contraindications that are misinterpreted. It is surprising that the infestigators hear from caregivers about the fear from the vaccines, and not about the fear from the diseases. Another important issue is the unfortunate vulnerability of this population to STD's, which the investigators repeatedly hear from caregivers that this is a non-issue for them, which is clearly a dangerous misconception [9].

Therefore, healthcare professionals are missing valuable information about possible risks and intervention opportunities among an at-risk population.

Objectives:

1. The investigators will systematically map the reasons for the delay and/or avoidance, and/or hesitance to vaccinate by conducting a large-scale evaluation of current and planned immunizations among persons of all ages who have special needs, intellectual and developmental disabilities and congenital anomalies (study group). The investigatorswill use a comprehensive questionnaire to collect this information, as well as focused discussion groups for in-depth qualitative investigations. The investigators will compare the data with their sibling's vaccination status and with recruits from the general population (control group).

According to the concept "Do not talk about us without us", The investigators will include persons with special needs and disabilities in the study and make all efforts to hear directly from them in focus groups or individually about their approach to vaccinations, including hesitancies and misconceptions about the procedure.

Hypotheses:

1. There is a higher prevalence of vaccine avoidance and delay among the study population.
2. The reasons for avoidance and/or delay are:

A. Fear of harm - The study population are perceived more fragile, hence more likely to adversely react to vaccines.

B. Misconceptions about their vulnerability to STD's, and false beliefs about neurodevelopmental effects of the vaccines themselves.

This is a descriptive qualitative and quantitative study. The Quantitative part consists of comprehensive questionnaires that The investigators will design for the study. The questionnaire will have five sections: 1. Sociodemographic data. 2. Current vaccination status. 3. Delay/hesitancy/avoidance - past present and future plans. 4. Reasons for delay/hesitancy/avoidance if exist. 5. Statements regarding vaccines benefits, safety, known side effects, and misconceptions, and the participants' level of agreement with these statements. All questionnaires will be filled out anonymously after consent to participate.

For the focused groups The investigators will recruit parents and other caregivers as well as persons with disabilities. The investigators will analyze these opened and free discussions, with limited opening remarks and follow up questions for clarification, in a qualitative manner and all themes, dilemmas and experiences will be presented accordingly.

It is based on questionnaires and focus groups studies, with control groups. The investigators will conduct the research in the Hadassah- Hebrew university medical center, in collaboration with associations and institutions that provide healthcare and support for the studied population and their families.

Since The investigators have ongoing collaborations with other academic and clinical institutions in other countries, it is possible for us to explore with them a fruitful collaboration in this research, and developing it to a multicenter study.

The investigators hopefully plan to recruit a total of one thousand participants.

The study population is our patients and their families that arrive for evaluations and treatments. The investigators plan to recruit more participants with the collaboration other associations and institutions. The population is consisted of persons with a variety of disabilities, namely intellectual and developmental disability, Down syndrome, congenital syndromes and genetic disorders.

The investigators will try to include as many persons as possible, excluding those who are reluctant to participate or did not provide minimal information in the questionnaires.

As part of the study procedure and presentation of the results, The investigators will aim to conceptualize tailored programs to increase vaccination confidence and adherence, and propose a follow-up interventional study.

• Study Type: Observational
• Enrollment (Estimated): 1000

Contacts and Locations

• Study Contact: Name: Ariel Tenenbaum, MD; Phone Number: +9720508573725; Email: tene@hadassah.org.il
• Study Contact Backup: Name: Hadas Lemberg, PhD; Phone Number: 00 972 2 6777572; Email: lhadas@hadassah.org.il

Study Locations

• Israel
  • Jerusalem, Israel, 92140
    • Recruiting
    • Hadassah Medical Center
    • Contact: Ariel Tenenbaum; Phone Number: 0508573725; Email: tene@hadassah.org.il

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Children with disabilities, chronic conditions and congenital anomalies. The parents will fiil out the questionnaires and participate in focus groups.

Description

Inclusion Criteria:

• Diagnosed children with disabilities, chronic diseases or congenital anomalies

Exclusion Criteria:

• Undiagnosed children
• Inadequate filled out questionnaires

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
study group and control group; Study group - children with chronic diseases, disabilities, or congenital anomalies. Control group - their siblings.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentages of children in the study group who are not vaccinated, partially vaccinated, or vaccinated late, in comparison with the percentages in the control group.	Percecntages as described above as well as description of reasons for vaccination avoidance, delay and hesitancy, obstacles in the way to vaccinate, approach to vaccines as detaled in the questionnaires.	2 years

Collaborators and Investigators

• Sponsor: Hadassah Medical Organization
• Collaborators: Merck Sharp & Dohme LLC
• Investigators: Principal Investigator: Ariel Tenenbaum, MD, Hadassah Medical Organization

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2023
• Primary Completion (Estimated): January 1, 2026
• Study Completion (Estimated): January 1, 2026

Study Registration Dates

• First Submitted: February 8, 2023
• First Submitted That Met QC Criteria: February 27, 2023
• First Posted (Actual): March 1, 2023

Study Record Updates

• Last Update Posted (Actual): April 3, 2025
• Last Update Submitted That Met QC Criteria: April 1, 2025
• Last Verified: September 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neurologic Manifestations; Nervous System Diseases; Mental Disorders; Neurobehavioral Manifestations; Neurodevelopmental Disorders; Intellectual Disability
• Other Study ID Numbers: Tenenbaum-HMO-CTIL

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No